Cor Vasa 2009, 51(7-8):488-490 | DOI: 10.33678/cor.2009.123

Infectious complications of long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension

David Ambrož*, Pavel Jansa, Jana Marešová, Michael Aschermann, Aleš Linhart
2. interní klinika kardiologie a angiologie, Všeobecná fakultní nemocnice a 1. lékařská fakulta Univerzity Karlovy, Praha, Česká republika

Aim: To evaluate the frequency of infectious and mechanical complications experienced by patients treated with continuous epoprostenol delivery using indwelling central venous catheters.

Methods: Retrospective analysis of data of 20 patients treated in the Pulmonary Hypertension Center of the Internal Department 2, General University Hospital and Charles University Medical School 1.

Results: The incidence of sepsis in our epoprostenol-treated patients was 0.18 per 1,000 days of epoprostenol administration. The frequency of indwelling catheter-related local infections was 0.48 per 1,000 days.

Conclusion: The rates of sepsis or local infectious complications are very low in well educated patients.

Keywords: Epoprostenol; Pulmonary hypertension; Sepsis

Published: July 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ambrož D, Jansa P, Marešová J, Aschermann M, Linhart A. Infectious complications of long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension. Cor Vasa. 2009;51(7-8):488-490. doi: 10.33678/cor.2009.123.
Download citation

References

  1. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France. Am J Respir Crit Care 2006;173:1023-30. Go to original source... Go to PubMed...
  2. Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007;30:104-9. Go to original source... Go to PubMed...
  3. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Ann Int Med 1991;115:343-9. Go to original source... Go to PubMed...
  4. Farber HV, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-65. Go to original source... Go to PubMed...
  5. Badesch DB, McLaughlin VV, Delcroix M. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:56S-61S. Go to original source... Go to PubMed...
  6. Sitbon O, Humbert M, Nunes H. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. J Am Coll Cardiol 2002;40: 780-8. Go to original source... Go to PubMed...
  7. Centers for Disease Control and Prevention; bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension. MMWR Morb Mortal Wkly Rep 2007; 56:170-2. Go to original source...
  8. Akagi S, Matsubara H, Ogawa A, et al. Prevention of catheter-related infections using a closed hub system in patients with pulmonary arterial hypertension. Circ J 2007;71:559-64. Go to original source... Go to PubMed...




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.